Indian stocks: Visit www.stage2stocks.com →

Canopy Growth Corporation

Stage 4 · Declining · week 4

As of Oct 22, 2026, Canopy Growth is in Stage 4, the downtrend phase, now in week 4 (since Sep 30, 2026). It closed at $0.67, 65.4% below its 52-week high and below its 200-day average, which is falling.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the… More about the company

$0.67
-1.04% today
$299M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CGC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 19w
S4 36w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 4w → S1 10w → S4 19w → S1 3w → S2 9w → S3 11w → S4 36w → S1 8w → S4 7w → S1 8w → S2 1w → S4 13w → S1 2w → S4 11w → S1 3w → S4 1w → S1 3w → S4 10w → S1 3w → S4 3w current
Total tracked: 165 weeks across 20 stage runs.

CGC among Drug Manufacturers - Specialty & Generic60th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…60CGCStage 4 · wk 423−28.9%
vs 52W High
-65.4%
$0.67 lo$1.92 hi
65.4% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 4
1w13w26w
Week 4, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-34.6%
200 DMA: $1.02 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.72x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-28.9%
3M
-25.2%
6M
-45.5%
YTD
-44.1%
1Y
-51.5%
Scan Membership
Breakout Watch
Latest: 2024-04-26
5 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 4 · Vol 0.72x
2026-10-21S4
Wk 4 · Vol 1.47x
2026-10-20S4
Wk 3 · Vol 0.51x
2026-10-19S4
Wk 3 · Vol 0.54x
2026-10-16S4
Wk 3 · Vol 0.77x
2026-10-15S4
Wk 3 · Vol 0.96x
2026-10-14S4
Wk 3 · Vol 1.49x
2026-10-13S4
Wk 2 · Vol 1.21x
2026-10-12S4
Wk 2 · Vol 1.80x
2026-10-09S4
Wk 2 · Vol 0.80x
2026-10-08S4
Wk 2 · Vol 1.42x
2026-10-07S4
Wk 2 · Vol 0.42x
Moving averages & range
50 DMA
$0.91
200 DMA
$1.02
52W High
$1.92
52W Low
$0.67
5D Low
$0.67
Resistance levels (recent highs)
20d High
$0.94
60d High
$1.07
120d High
$1.15
250d High
$1.92
Next resistance
+41.7%
to 20d High
ROE
-39.5%
Profit margin -79.2%
Dividend Yield
0.00%
P/B 0.6

Canopy Growth: quick answers

What stage is Canopy Growth in?

As of Oct 22, 2026, Canopy Growth (CGC) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 30, 2026 and is in week 4. What the four stages mean

Is Canopy Growth in an uptrend?

No. Canopy Growth is in a Stage 4 downtrend. It trades 34.6% below its 200-day average, which is falling.

How far is Canopy Growth from its 52-week high?

Canopy Growth closed at $0.67 on Oct 22, 2026, 65.4% below its 52-week high of $1.92. Its 52-week low is $0.67.

How has Canopy Growth performed over the past year?

As of Oct 22, 2026, Canopy Growth is down 51.5% over the past year and down 44.1% so far in 2026.

Which sector and industry is Canopy Growth in?

Canopy Growth is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.